(Q34450671)

2 August 2017

1 reference

title

Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis (English)

1 reference

2 August 2017

Perfetto EM

1

1 reference

2 August 2017

Mullins CD

series ordinal

2

1 reference

2 August 2017

Subedi P

series ordinal

3

1 reference

2 August 2017

Li-McLeod J

series ordinal

4

1 reference

2 August 2017

language of work or name

1 reference

1 October 2001

1 reference

2 August 2017

Clinical Therapeutics

1 reference

2 August 2017

23

1 reference

2 August 2017

1747-1772

1 reference

2 August 2017

10

1 reference

Epidemiology of chronic airways disease

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Treatment cost of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

The patient's burden: physical and psychological effects of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Epidemiology and pharmacoeconomic issues relating to acute respiratory tract infections and acute uncomplicated infections of the urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Acute exacerbations of chronic bronchitis: an international comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Antibiotics in acute bronchitis and exacerbations of chronic bronchitis: what is general practitioners' habit?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Role of infection in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

How do we achieve cost-effective options in lower respiratory tract infection therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. A double-blind crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

US regulation of pharmaceutical outcomes research

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Using outcomes research in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Patient Outcomes Research Teams: contribution to outcomes and effectiveness research

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparison of ceftibuten versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: Sparfloxacin versus clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Ofloxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbation of chronic bronchitis. Study of Ofloxacin in Lower Respiratory Tract Infections Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis. The Cefdinir Bronchitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

International study comparing cefdinir and cefuroxime axetil in the treatment of patients with acute exacerbation of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Sequential therapy with cefuroxime followed by cefuroxime axetil in acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Five-day dirithromycin therapy is as effective as seven-day erythromycin therapy for acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Azithromycin versus pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Azithromycin compared with clarithromycin in the treatment of adult patients with acute purulent tracheobronchitis: a cost of illness study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Randomised controlled trial of antibiotics in patients with cough and purulent sputum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Dirithromycin versus amoxiclav in the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Acute bronchitis: course of symptoms and restrictions in patients' daily activities.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Antibiotics in acute bronchitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980142-9

7 January 2021

10.1016/S0149-2918(01)80142-9

Identifiers

DOI

1 reference

2 August 2017

1 reference